Hereditary Angioedema Therapies in the United States: Movement Toward an International Treatment Consensus

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 623-630

  Riedl, Marc ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute treatment; Hereditary angioedema; Individualized therapy; Prophylaxis

Indexed keywords

ANALGESIC AGENT; ANDROGEN; ANTIFIBRINOLYTIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; PLACEBO; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FLUID THERAPY; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INDICATION; UNITED STATES;

ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; DISEASE MANAGEMENT; HUMANS; KALLIKREINS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, BRADYKININ B2; UNITED STATES;

EID: 84858608697     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.003     Document Type: Article

References (31)

1. Gompels M.M., Lock R.J., Abinun M., et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005, 139:379-394.
2. Agostoni A., Aygören-Pürsün E., Binkley K.E., et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004, 114:S51-S131.
3. Craig T.J., Riedl M., Dykewicz M.S., et al. When is prophylaxis for hereditary angioedema necessary?. Ann Allergy Asthma Immunol 2009, 102:366-372.
4. Lumry W.R., Castaldo A.J., Vernon M.K., et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010, 31:407-414.
5. Wilson D.A., Bork K., Shea E.P., et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104:314-320.
6. Zilberberg M., Jacobsen T., Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc 2010, 31:511-519.
7. Zilberberg M., Nathanson B., Jacobsen T., et al. Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004-2007. Allergy Asthma Proc 2011, 32:1-7.
8. Roche O., Blanch A., Caballero T., et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005, 94:498-503.
9. Lunn M.L., Santos C.B., Craig T.J. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?. Ann Allergy Asthma Immunol 2010, 104:211-214.
10. Maurer M., Magerl M. Hereditary angioedema: an update on available therapeutic options. J Dtsch Dermatol Ges 2010, 8:663-672.
11. Riedl M., Gower R.G., Chrvala C.A. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol 2011, 106:316-322.e4.
12. Frank M.M. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006, 26:653-668.
13. Zuraw B.L. Clinical practice: hereditary angioedema. N Engl J Med 2008, 359:1027-1036.
14. Cinryze - Highlights of Prescribing Information US Food and Drug Administration, Accessed October 12, 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM129918.pdf.
15. Berinert - Highlights of Prescribing Information US Food and Drug Administration, Accessed October 12, 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM186268.pdf.
16. Kalbitor - Highlights of Prescribing Information US Food and Drug Administration, Accessed October 12, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125277lbl.pdf.
17. Firazyr - Highlights of Prescribing Information US Food and Drug Administration, Accessed October 12, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022150s000lbl.pdf.
18. Ruconest Summary of Product Characteristics Accessed May 17, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001223/WC500098542.pdf.
19. Zuraw B.L., Busse P.J., White M., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010, 363:513-522.
20. Craig T.J., Levy R.J., Wasserman R.L., et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009, 124:801-808.
21. Cicardi M., Levy R.J., McNeil D.L., et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010, 363:523-531.
22. Levy R.J., Lumry W.R., McNeil D.L., et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104:523-529.
23. Cicardi M., Banerji A., Bracho F., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010, 363:532-541.
24. 2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011, 107:529-537.
25. Zuraw B., Cicardi M., Levy R.J., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010, 126:821-827.e14.
26. Kalbitor - Risk Evaluation and Mitigation Strategy US Food and Drug Administration, Accessed October 12, 2011. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM261985.pdf.
27. Bygum A., Andersen K.E., Mikkelsen C.S. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009, 19:147-151.
28. Kreuz W., Martinez-Saguer I., Aygören-Pürsün E., et al. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009, 49:1987-1995.
29. Bowen T., Cicardi M., Farkas H., et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010, 6:24.
30. Longhurst H.J., Farkas H., Craig T., et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010, 6:22.
31. Aygören-Pürsün E., Martinez-Saguer I., Rusicke E., et al. On-demand treatment and home therapy of hereditary angioedema in Germany: the Frankfurt experience. Allergy Asthma Clin Immunol 2010, 6:21.